<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00548197</url>
  </required_header>
  <id_info>
    <org_study_id>85-A-57</org_study_id>
    <nct_id>NCT00548197</nct_id>
  </id_info>
  <brief_title>Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment</brief_title>
  <official_title>Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitreoretinal surgery for epiretinal proliferation tractional retinal detachment associated
      with proliferative diabetic retinopathy (PDR) is often complicated by hemorrhage from
      fibrovascular tissue. To control the bleeding during tissue dissection multiple measures and
      techniques are used.

      Bevacizumab is an anti VEGF antibody which has been used to induce regression of ocular
      neovascularization. Its intraocular injection has been increasingly used for treatment of
      choroidal neovascularization (CNV) associated with age related macular degeneration (AMD)
      with fairly good success.Also it has been shown to be effective for treatment of PDR
      complicated with vitreous hemorrhage and iris neovascularization. We hypothesized that if
      anti-angiogenic agents, such as bevacizumab are injected into the vitreous cavity before
      vitrectomy in cases of PDR; there may be partial regression of neovascularization resulting
      in less intraoperative (and postoperative) hemorrhage. This can make the operation easier and
      shorter and lessen the need for intraocular cautery..

      In this study diabetic patients who are candidated for vitrectomy with similar complexity
      scores will be randomized to preoperative injection or no injection of 2.5 mg Bevacizumab .In
      the injection group, 2.5 mg of bevacizumab (0.1 ml of commercially available Avastin vial,
      Genentech, inc. South San Francisco, CA) will be injected into the vitreous 3-5 days before
      operation.

      During each operation, the number of endodiathermy applications, backflush needle
      applications and the duration of surgery will be recorded by an independent observer. Also,
      type of tamponade, post operation vitreous hemorrhage and 3 months postoperative visual
      acuities wil be recorded. all these parameters will be compared in two groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligibility criteria:

      Diabetic tractional retinal detachment-complexity score between 4 and 8

      Main outcome measures:

      best corrected visual acuity-anatomic condition of the retine(re-attachment of the retina)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>last follow up, an average of 7 months post-operation</time_frame>
    <description>Post operative best corrected visual acuity ( best distance vision with eyeglasses or contact lenses)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anatomic Status of the Retina</measure>
    <time_frame>Last follow up, an average of 7 months post-operation</time_frame>
    <description>Number of Participants with Postoperative Vitreous Hemorrhage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Intravitreal Bevacizumab Injection</condition>
  <condition>Pars Plana Vitrectomy</condition>
  <condition>Tractional Retinal Detachment</condition>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal Bevacizumab will be injected 2.5 mg IVB 3-5 days before operation in diabetic patients who were candidates for vitrectomy before performing pars plana vitrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no injection before performing pars plana vitrectomy in diabetic patients who were candidates for vitrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>one intravitreal injection of 2.5 mg Bevacizumab 3-5 days before performing pars plana vitrectomy</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Brand name of Bevacizumab is Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Those patients with tractional retinal detachment who are candidated for pars plana
             vitrectomy.

          -  Complexity score between 4 and 8.

        Exclusion Criteria:

          -  Previous vitreoretinal surgery.

          -  Presence of any other vitreoretinal pathology such as past or present uveitis, and
             retinal artery or vein occlusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehdi Modarres, MD</last_name>
    <role>Study Director</role>
    <affiliation>Iran University of Medical Sciences(IUMS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rasool Akram Hospital</name>
      <address>
        <city>Tehran</city>
        <zip>14455-364</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006 Mar;26(3):275-8.</citation>
    <PMID>16508426</PMID>
  </reference>
  <reference>
    <citation>Castellarin A, Grigorian R, Bhagat N, Del Priore L, Zarbin MA. Vitrectomy with silicone oil infusion in severe diabetic retinopathy. Br J Ophthalmol. 2003 Mar;87(3):318-21.</citation>
    <PMID>12598446</PMID>
  </reference>
  <reference>
    <citation>Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol. 2006 Jul;142(1):158-60.</citation>
    <PMID>16815268</PMID>
  </reference>
  <verification_date>February 2007</verification_date>
  <study_first_submitted>October 22, 2007</study_first_submitted>
  <study_first_submitted_qc>October 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2007</study_first_posted>
  <results_first_submitted>March 1, 2018</results_first_submitted>
  <results_first_submitted_qc>October 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 16, 2018</results_first_posted>
  <last_update_submitted>October 13, 2018</last_update_submitted>
  <last_update_submitted_qc>October 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intravitreal Bevacizumab injection</keyword>
  <keyword>Pars plana vitrectomy</keyword>
  <keyword>tractional retinal detachment</keyword>
  <keyword>Diabetic retinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Retinal Detachment</mesh_term>
    <mesh_term>Dissociative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>no injection before performing pars plana vitrectomy in diabetic patients who were candidates for vitrectomy</description>
        </group>
        <group group_id="P2">
          <title>Intervention Group</title>
          <description>Intravitreal Bevacizumab will be injected 2.5 mg IVB 3-5 days before operation in diabetic patients who were candidates for vitrectomy before performing pars plana vitrectomy
Bevacizumab: one intravitreal injection of 2.5 mg Bevacizumab 3-5 days before performing pars plana vitrectomy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>Intravitreal Bevacizumab will be injected 2.5 mg IVB 3-5 days before operation in diabetic patients who were candidates for vitrectomy before performing pars plana vitrectomy
Bevacizumab: one intravitreal injection of 2.5 mg Bevacizumab 3-5 days before performing pars plana vitrectomy</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>no injection before performing pars plana vitrectomy in diabetic patients who were candidates for vitrectomy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.8" spread="11.3"/>
                    <measurement group_id="B2" value="53.2" spread="11.7"/>
                    <measurement group_id="B3" value="54.63" spread="11.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Best Corrected Visual Acuity</title>
        <description>Post operative best corrected visual acuity ( best distance vision with eyeglasses or contact lenses)</description>
        <time_frame>last follow up, an average of 7 months post-operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Intravitreal Bevacizumab will be injected 2.5 mg IVB 3-5 days before operation in diabetic patients who were candidates for vitrectomy before performing pars plana vitrectomy
Bevacizumab: one intravitreal injection of 2.5 mg Bevacizumab 3-5 days before performing pars plana vitrectomy</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>no injection before performing pars plana vitrectomy in diabetic patients who were candidates for vitrectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Best Corrected Visual Acuity</title>
          <description>Post operative best corrected visual acuity ( best distance vision with eyeglasses or contact lenses)</description>
          <units>LogMar</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.4"/>
                    <measurement group_id="O2" value="1.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anatomic Status of the Retina</title>
        <description>Number of Participants with Postoperative Vitreous Hemorrhage</description>
        <time_frame>Last follow up, an average of 7 months post-operation</time_frame>
        <population>Postoperative Vitreous Hemorrhage</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Intravitreal Bevacizumab will be injected 2.5 mg IVB 3-5 days before operation in diabetic patients who were candidates for vitrectomy before performing pars plana vitrectomy
Bevacizumab: one intravitreal injection of 2.5 mg Bevacizumab 3-5 days before performing pars plana vitrectomy</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>no injection before performing pars plana vitrectomy in diabetic patients who were candidates for vitrectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Anatomic Status of the Retina</title>
          <description>Number of Participants with Postoperative Vitreous Hemorrhage</description>
          <population>Postoperative Vitreous Hemorrhage</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>Intravitreal Bevacizumab will be injected 2.5 mg IVB 3-5 days before operation in diabetic patients who were candidates for vitrectomy before performing pars plana vitrectomy
Bevacizumab: one intravitreal injection of 2.5 mg Bevacizumab 3-5 days before performing pars plana vitrectomy</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>no injection before performing pars plana vitrectomy in diabetic patients who were candidates for vitrectomy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Inferior rhegmatogenous retinal detachment and perisillicone proliferations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mehdi Modarres</name_or_title>
      <organization>Iran university of medical Sciences</organization>
      <phone>009888602217</phone>
      <email>mmodarres51@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

